Related Experiment Video
Updated: May 27, 2026
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Post percutaneous coronary intervention antiplatelet therapy: current perceptions, prospects and perplexity
Sadip Pant1, Pritam Neupane, K C Ramesh
1Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, 72205 AR, USA.sadippant@hotmail.com
Insights
Dual antiplatelet therapy (DAT) is crucial after percutaneous coronary intervention (PCI) with stents. Duration varies by stent type (bare metal vs. drug-eluting) and patient risk, balancing thrombosis prevention with surgical needs.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Dual antiplatelet therapy (DAT) is standard post-percutaneous coronary intervention (PCI) due to platelet activation and coagulation cascade following stent placement.
- Stent healing varies: bare metal stents (BMS) re-epithelialize in 6-8 weeks, while drug-eluting stents (DES) have delayed healing, potentially taking months to years for neointima formation.
Purpose of the Study:
- To review the indications, duration, and management of dual antiplatelet therapy (DAT) in patients undergoing percutaneous coronary intervention (PCI).
- To discuss the role of different antiplatelet agents and considerations for surgical management during DAT.
Main Methods:
- Review of current guidelines and clinical practices regarding dual antiplatelet therapy (DAT) after PCI.
- Discussion of pharmacological properties of antiplatelet agents like clopidogrel, prasugrel, ticagrelor, and cangrelor.
- Analysis of factors influencing DAT duration, including stent type, patient thrombotic risk, and surgical interventions.
Main Results:
- DAT duration is typically 3 months for BMS and at least 1 year for DES, with prolonged therapy for high-risk patients.
- DAT continuation is recommended during non-cardiac surgeries if bleeding is controllable and does not compromise surgical outcomes.
- Prasugrel offers advantages over clopidogrel, especially in diabetic patients with acute coronary syndrome undergoing PCI; triple therapy is reserved for specific cases.
Conclusions:
- Optimizing dual antiplatelet therapy (DAT) duration and agent selection is critical for preventing stent thrombosis after PCI.
- Careful consideration of bleeding risk versus thrombotic risk is essential when managing DAT in patients requiring surgery.
- Emerging antiplatelet agents like ticagrelor and cangrelor show promise and are under active clinical investigation.
Abstract:
Dual antiplatelet therapy (DAT) has become standard care for patients undergoing percutaneous coronary intervention (PCI). Following balloon injury and stent placement, the intima at the site is distressed, resulting in the activation of coagulation cascade and platelets. In the case of bare metal stents (BMS), it takes six to eight weeks for the stent surface to be covered with neointima. However, in the case of a drug-eluting stent (DES), the process of healing is delayed and neointima may not form for months or even years. To prevent the formation of platelet thrombi, dual antiplatelet therapy is given as a combination of aspirin and clopidogrel for three months in a case of BMS and for a minimum of one year in a case of DES. A prolonged duration of therapy is often required for a subset of patients who are highly prone to thrombus formation. During most non-cardiac surgeries, dual antiplatelet therapy should be continued if bleeding can be directly controlled and excessive bleeding will have no adverse effect on the outcome of surgery. Prasugrel, another thienopyridine, is more potent and faster acting than clopidogrel, and is therefore of great value in cases of acute coronary syndrome during PCI, particularly in diabetics. Triple drug therapy, by adding cilastozol, is reserved for some selected thrombotic lesions. Ticagrelor and cangrelor are two new antiplatelet agents undergoing various clinical trials. (Cardiol J 2011; 18, 6: 712-717).
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:26Angina IV: Management
01:26Atherosclerosis III: Management
01:28Acute Coronary Syndrome IV: Interprofessional Care